Is the worst still to come for this year's most beaten down ETF?
Biotech stocks have suffered extreme losses recently amid the broader market sell-off. The SPDR S&P biotech ETF — XBI — has plunged more than 30 percent year to date. Excluding leveraged ETFs, XBI has fallen more than any other exchange-traded fund in 2016, as of Friday's close.
Most investors are more familiar with the larger iShares Nasdaq Biotech ETF (IBB), which is down a somewhat milder 24 percent this year. While both ETFs contain many of the same components, IBB is most heavily weighted toward the bigger biotech names; 38 percent of the IBB is composed of just four stocks, Celgene, Amgen, Biogen and Gilead. These stocks have held up better than many of the smaller companies contained within the (XBI), which are generally seen as riskier.
According to Susquehanna head of derivatives strategy Stacey Gilbert, options traders are expecting more big swings ahead for XBI.
"I don't think we're out of the woods in terms of this sector becoming less volatile," Gilbert said Friday on CNBC's "Trading Nation."
However, the volatility cuts both ways. As stocks on the whole rise Tuesday, the XBI is up as much as 4 percent, while the IBB is up just 2 percent.
Looking at the chart of XBI, Todd Gordon of TradingAnalysis.com said the ETF has held above an important support level at $45, which should set it up for more short-term gains.
"[XBI] might have a shot to regain its footing," Gordon said Friday on "Trading Nation." "I don't think it's going to lead us up in 2016, but I think some of the selling will abate."